Beijing Luzhu Biotechnology Co., Ltd. (2480)

Overview

Beijing Luzhu Biotechnology Co., Ltd., established in 2001 and headquartered in Beijing, China, operates in the biotechnology industry with a primary focus on the research, development, production, and sale of human vaccines and therapeutic biologics. The company's mission is to prevent and control infectious diseases, while simultaneously addressing cancer and autoimmune diseases within the Chinese market. To achieve its goals, Beijing Luzhu Biotechnology engages in strategic cooperation with partners like Tianjin Ringpu Bio-Technology Co., Ltd. for the development of monoclonal antibody drugs and genetically engineered vaccines, notably for pets.

Products and Services

The company's product pipeline includes clinical-stage product candidates, pre-clinical-stage product candidates, and various immunoreagent enzyme-linked kits, in addition to a range of out-licensed products.

• Clinical-Stage Product Candidates:
  • LZ901: A recombinant herpes zoster vaccine designed to prevent shingles.
  • K3: A recombinant human anti-TNF-a monoclonal antibody injection used for treating several autoimmune diseases, including rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis.
  • K193: A bispecific antibody injection aimed at treating B cell leukemia and lymphoma.
• Pre-Clinical-Stage Product Candidates:
  • Recombinant Varicella Vaccine: Intended for the prevention of chickenpox, caused by the varicella-zoster virus.
  • Recombinant Rabies Vaccine: Developed to prevent rabies in humans.
  • K333: A bispecific antibody injection product focused on the treatment of myeloid leukemia.
  • K1932: Another bispecific antibody injection targeting B cell lymphoma.
• Immunoreagent Enzyme-Linked Kits: These are utilized for the detection of antibodies against infectious diseases, including:
  • Group A, C, Y, W135 meningococcal polysaccharide IgG and haemophilus influenzae Type b polysaccharide IgG antibody detection kits.
• Out-Licensed Products: The company also markets a range of vaccines that have been out-licensed, including:
  • Influenzae type b conjugate, Group ACYW135 meningococcal polysaccharide, Group A and C meningococcal - haemophilus influenzae type b conjugate, and more.